title: Wash-out of DMSO does not improve the speed of engraftment of cord blood transplantation: follow-up of 46 adult patients with units shipped from a single cord blood bank.
abstract: BACKGROUND
  Prolonged periods of marrow hypoplasia have been a problem in cord blood transplantation. DMSO is thought to produce osmotic shock to the progenitors when the thawed cells are infused into the patients. To solve this problem, a 2x dilution method originally developed in the New York Blood Center showed earlier myeloid engraftment,1 although follow-up clinical studies have not performed.
  
  
  METHODS
  To clarify the influence of the removal of DMSO by this method on the speed of engraftment in unrelated cord blood transplantation, 46 adult patients with cord blood units processed by the Tokyo Cord Blood Bank from September 1998 to March 31, 2002 were studied. Twenty-four patients received 2.6 +/- 0.71 x 10(7) nucleated cells per kg without washing (nonwashed group), while 22 patients were received 2.7 +/- 0.52 x 10(7) nucleated cells per kg after 2x dilution washing (washed group).
  
  
  RESULTS
  The cumulative incidence of engraftment was not significantly different between the two groups. Median neutrophil recovery (>/=5 x 10(9)/L) in the nonwashed and washed groups was 26 and 25 days, respectively, and the median platelet recovery (>/=20 x 10(9)/L) in patients with myeloid engraftment was 44 and 40 days, respectively (NS). On the other hand, the doses of CFCs and CD34+ cells showed the influence on myeloid and platelet recovery.
  
  
  CONCLUSIONS
  A 2x dilution after thawing cord blood did not result in the improvement of myeloid engraftment speed.
authors.affiliation: Division of Cell Processing, The Institute of Medical Science, University of Tokyo, Tokyo, 4-6-1, Japan.
authors.forename: Tokiko
authors.initials: T
authors.lastname: Nagamura-Inoue
authors.forename: Mika
authors.initials: M
authors.lastname: Shioya
authors.forename: Michiko
authors.initials: M
authors.lastname: Sugo
authors.forename: Yan
authors.initials: Y
authors.lastname: Cui
authors.forename: Atsuko
authors.initials: A
authors.lastname: Takahashi
authors.forename: Satomi
authors.initials: S
authors.lastname: Tomita
authors.forename: Yizhou
authors.initials: Y
authors.lastname: Zheng
authors.forename: Kei
authors.initials: K
authors.lastname: Takada
authors.forename: Hideki
authors.initials: H
authors.lastname: Kodo
authors.forename: Shigetaka
authors.initials: S
authors.lastname: Asano
authors.forename: Tsuneo A
authors.initials: TA
authors.lastname: Takahashi
mesh_terms: D000293:Adolescent; D000328:Adult; D018952:Antigens, CD34 / Q000032:analysis; D001771:Blood Banks; D001793:Blood Preservation / Q000379:methods; D036101:Cord Blood Stem Cell Transplantation / Q000379:methods* / Q000706:statistics & numerical data; D003451:Cryoprotective Agents; D004121:Dimethyl Sulfoxide; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000401:mortality; D006412:Hematopoietic Stem Cells / Q000737:chemistry / Q000166:cytology; D006650:Histocompatibility Testing; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000166:cytology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality / Q000628:therapy*; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate
chemical_list: D018952:Antigens, CD34; D003451:Cryoprotective Agents; D004121:Dimethyl Sulfoxide